Lead Product(s): Sacubitril valsartan sodium hydrate
Therapeutic Area: Cardiology/Vascular Diseases
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Otsuka Chemical Co Ltd
Deal Size: Undisclosed Upfront Cash: $90.0 million
Deal Type: Agreement March 02, 2020
Under the terms of this agreement, Novartis Pharma and Otsuka will jointly undertake the promotion of LCZ696 to healthcare practitioners in Japan.